Halozyme Therapeutics (HALO) PT Raised to $92 at Citizens on Strong Quarter

Citizens analyst Jason Butler raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $92.00 (from $91.00) while maintaining a Market Outperform rating.

The analyst commented, "Strong quarter driven by indication and global expansion of ENHANZE partnered products; we reiterate our Market Outperform rating and increase our risk-adjusted, DCF-derived price target from $91 to $92 on Halozyme. Yesterday afternoon, Halozyme reported 3Q25 financial results above our and consensus estimates and raised 2025 guidance on the top and bottom lines. The beat was once again driven by stronger-than-anticipated royalty growth and the midpoint of the new guidance range now reflects Y/Y royalty growth >50%. We have increased our estimates for 2025 and increased our royalty revenue projection for 2026. We note that we continue to expect the company to achieve 2026 adjusted EBITDA >$1Bn, a milestone it would achieve a year ahead of prior long-term guidance."

You May Also Be Interested In

• Freedom Broker Downgrades Flexsteel (FLXS) to Hold
• Noble Capital Starts Xerox (XRX) at Outperform
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance